Evidence map›Paper›PMID 40400979›Full record

ReviewJournal of thoracic disease2025

The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024].

Nan Jia, Meiling Jin, Yun Liu, Nan Su, Ying Sun, Wei Tang, Gang Wang, Hua Xie, Jiaxing Xie, Min Xie and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nan Jia *Department of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-7164-6947
Meiling Jin *Department of Allergy, Zhongshan Hospital of Fudan University, Shanghai, China.
Yun Liu *Department of Allergy, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0003-4564-6879
Nan Su *Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.ORCID https://orcid.org/0009-0003-9189-2779
Ying Sun *School of Basic Medical Sciences, Capital Medical University, Beijing, China.
Wei Tang *Department of Respiratory and Critical Care Medicine, Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-0789-9971
Gang Wang *Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-5048-6606
Hua Xie *Respiratory Medicine and Allergic Disease Diagnosis and Treatment Center, General Hospital of Northern Theater Command, Shenyang, China.ORCID https://orcid.org/0000-0003-4904-0698
Jiaxing Xie *National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0001-6462-6676
Min Xie *Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.ORCID https://orcid.org/0000-0003-4052-1647
Xin Yao *Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-1301-3631
Huanping Zhang *Department of Allergy Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.ORCID https://orcid.org/0000-0003-2263-6774
Ruchong ChenDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0001-5376-8230
Chuntao LiuDepartment of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Jing LiDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-6459-7470

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Type 2 (T2) inflammatory respiratory diseases encompass a range of conditions characterized by inflammation affecting the airways and lung parenchyma, with their pathogenesis rooted in T2 inflammation. Biological treatments that mitigate T2 inflammation revolutionize the therapeutic landscape for these respiratory diseases. However, there are decision-making difficulties in terms of the target population, timing of initiation, and type selection for biological targeted therapy. Methods: Search strategies were focused on relevant issues related to T2 inflammatory respiratory diseases from PubMed with search date from 2014 to 2024. The quality of evidence and grading recommendations were assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Consensus was achieved through two rounds of anonymous voting with a strong recommendation demanding at least 70% approval from the participants. Results: A total of 370 basic research results and clinical evidence-based medical data were collected and reviewed. The latest research advances, clinical evidence, and expert insights relating to the use of biological treatments aiming at T2 inflammation in respiratory diseases and their co-morbidities were discussed rigorously and iteratively by an expert panel, and a consensus report with recommendations is presented. Conclusions: This consensus outlines the pathogenesis, assessment of T2 inflammation, biological therapies targeted at T2 inflammation, and management strategies for T2 inflammatory respiratory diseases and their comorbidities. It will serve as a valuable guide for clinicians in China, empowering them to diagnose and manage these conditions more effectively.

Indexed as

respiratory diseasessevere asthmatype 2 biologic therapies (T2 biologic therapies)Type 2 inflammation (T2 inflammation)

Identifiers

PMID40400979
PMCPMC12090159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.